Research location
Mizunami
Gifu, Japan
Advertisement
Research activity in Mizunami
Gifu, JapanCureCurrent currently publishes aggregate city-level research activity for this location: 9 trials and 9 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Mizunami
9 linked trials · page 1 of 1Dose-range Finding Efficacy and Safety Study for QBW251 in COPD PatientsNCT04072887 · 2019-09-12 · 1 site observation
COMPLETED
Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma TreatmentNCT03052517 · 2017-03-21 · 1 site observation
TERMINATED
Asthma Control, Quality of Life and Emotional Feelings in a Real Life SettingNCT02640742 · 2015-12-18 · 1 site observation
COMPLETED
Pharmacological Effect of Lysozyme for Chronic Obstructive Pulmonary Disease and Asthma With Sputum SymptomNCT01715493 · 2012-10-01 · 1 site observation
COMPLETED
Safety and Efficacy of Mometasone Furoate Delivered Via Concept1 Device or Twisthaler® Device in Adult and Adolescent Patients With Persistent AsthmaNCT01555151 · 2012-07-01 · 1 site observation
COMPLETED
Dose Finding Study for QAW039 in AsthmaNCT01437735 · 2011-08-01 · 1 site observation
COMPLETED
A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type DementiaNCT01276353 · 2011-01-01 · 1 site observation
COMPLETED
Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Clinical Safety and Effectiveness in Patients With Alzheimer's DiseaseNCT01251718 · 2010-12-01 · 1 site observation
COMPLETED
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mgNCT00919477 · 2009-05-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.